Analyzing Cost of Revenue: Corcept Therapeutics Incorporated and Bausch Health Companies Inc.

Cost of Revenue Trends in Pharma: Bausch vs. Corcept

__timestampBausch Health Companies Inc.Corcept Therapeutics Incorporated
Wednesday, January 1, 20142254600000882000
Thursday, January 1, 201526450000001361000
Friday, January 1, 201626110000002058000
Sunday, January 1, 201725480000003554000
Monday, January 1, 201823510000005215000
Tuesday, January 1, 201923500000005504000
Wednesday, January 1, 202022490000005582000
Friday, January 1, 202123940000005281000
Saturday, January 1, 202223640000005385000
Sunday, January 1, 202325590000006481000
Loading chart...

Data in motion

Analyzing Cost of Revenue: A Tale of Two Companies

In the ever-evolving landscape of the pharmaceutical industry, understanding cost structures is crucial. This analysis delves into the cost of revenue for Corcept Therapeutics Incorporated and Bausch Health Companies Inc. over the past decade.

Bausch Health Companies Inc.

From 2014 to 2023, Bausch Health's cost of revenue has shown a relatively stable trend, averaging around $2.43 billion annually. The highest cost was recorded in 2015, with a 17% increase from the previous year, while 2020 marked the lowest point.

Corcept Therapeutics Incorporated

In contrast, Corcept Therapeutics has experienced a significant upward trajectory. Starting at just $882,000 in 2014, their cost of revenue surged by over 600% to $6.48 million by 2023. This growth reflects Corcept's expanding market presence and operational scale.

Conclusion

These insights highlight the diverse financial strategies and market dynamics within the pharmaceutical sector.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025